cladribine has been researched along with Disease Exacerbation in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (21.74) | 18.2507 |
| 2000's | 14 (20.29) | 29.6817 |
| 2010's | 29 (42.03) | 24.3611 |
| 2020's | 11 (15.94) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Harbi, T; Alroughani, R; Ampapa, R; Barnett, M; Bergamaschi, R; Bovis, F; Boz, C; Butler, E; Butzkueven, H; Buzzard, K; Cartechini, E; Castillo-Triviño, T; Cristiano, E; Csepany, T; de Gans, K; Dominguez, JA; Duquette, P; Eichau, S; Ferraro, D; Fragoso, Y; Gerlach, O; Girard, M; Gouider, R; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Havrdova, EK; Hodgkinson, S; Horakova, D; Hughes, S; Iuliano, G; Izquierdo, G; Kalincik, T; Kappos, L; Kermode, A; Lechner-Scott, J; Lugaresi, A; Macdonell, R; Malpas, C; McCombe, P; Moore, F; Onofrj, M; Ozakbas, S; Petersen, T; Prat, A; Prevost, J; Rozsa, C; Saladino, ML; Sanchez-Menoyo, JL; Sempere, AP; Sharmin, S; Shaw, C; Shaygannejad, V; Shuey, N; Sidhom, Y; Simo, M; Singhal, B; Sirbu, CA; Skibina, O; Slee, M; Sola, P; Solaro, C; Sormani, MP; Soysal, A; Spitaleri, D; Taylor, B; Terzi, M; Trojano, M; Turkoglu, R; van der Walt, A; van Pesch, V; Van Wijmeersch, B; Vucic, S; Yamout, B | 1 |
| Alexandri, N; Battaglini, M; Cortese, R; De Stefano, N; Gentile, G; Inderyas, M; Luchetti, L; Sormani, MP | 1 |
| Bell Gorrod, H; Damian, D; Harty, GT; Hettle, R; Latimer, NR; Wong, SL | 1 |
| Costa, J; Guerreiro, R; Miguel, LS; Pinheiro, B | 1 |
| Boyko, AN; Evdoshenko, EP; Khachanova, NV; Melnikov, MV; Rozenson, OL; Sivertseva, SA; Spirin, NN; Vasilyev, AV | 1 |
| AbdelRaheem, HG; Elsantiel, HIE; Elsherif, NHK; Makkeyah, SM; Ragab, IA; Tantawy, AAG | 1 |
| Annovazzi, P; Barcella, V; Baroncini, D; Barone, S; Barrilà, C; Binello, E; Bonavita, S; Cerqua, R; Clerici, VT; Clerico, M; Cocco, E; Cordioli, C; Di Sapio, A; Esposito, S; Fenu, G; Frau, J; Frigeni, B; Grasso, R; Ippolito, D; La Gioia, S; Landi, D; Lanzillo, R; Laroni, A; Lavorgna, L; Maniscalco, GT; Mataluni, G; Pareja-Gutierrez, L; Perini, P; Pontecorvo, S; Rasia, S; Repice, AM; Russo, CV; Saccà, F; Sartori, A; Signori, A; Signoriello, E; Sormani, MP; Stromillo, ML; Visconti, A; Zarbo, IR | 1 |
| Abeykoon, JP; Bennani, NN; Call, TG; Davidge-Pitts, CJ; Go, RS; Goyal, G; Hook, CC; Hu, M; Inwards, DJ; Koster, MJ; Pardanani, A; Ravindran, A; Rech, KL; Ryu, JH; Shah, MV; Tobin, WO; Vassallo, R; Young, JR | 1 |
| Bowen, JD; Cree, BAC; Damian, D; Dangond, F; Galazka, A; Grosso, M; Hartung, HP; Hughes, B; Hyvert, Y; Jones, DL; Leist, TP; Vermersch, P | 1 |
| Gold, R; Hoffmann, O | 1 |
| Beiki, O; Clerico, M; Del Giovane, C; Filippini, G; Fredrikson, S; Mattoscio, M; Piazza, F; Salanti, G; Scalfari, A; Tramacere, I | 1 |
| Harty, G; Hettle, R; Wong, SL | 1 |
| Dahm, AEA; Dybedal, I; Habberstad, AH; Randen, U; Spetalen, S; Tjønnfjord, GE; Tran, HTT | 1 |
| Comi, G; Cook, S; Dangond, F; Giovannoni, G; Hicking, C; Rammohan, KW; Rieckmann, P; Soelberg Sorensen, P; Vermersch, P | 1 |
| Grieb, P; Rejdak, K; Stelmasiak, Z | 1 |
| Berardi, A; Harty, G; Siddiqui, MK; Treharne, C; Wong, SL | 1 |
| Polanco, A; Poveda, JL; Rubio-Rodríguez, D; Rubio-Terrés, C; Torres, C; Trillo, JL | 1 |
| Damian, D; Gorrod, HB; Harty, GT; Hettle, R; Latimer, NR; Wong, SL | 1 |
| Pardanani, A | 2 |
| Abdulrezzak, U; Cetin, M; Kaynar, L; Keklik, M; Kontas, O; Sivgin, S | 1 |
| Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Casset-Semanaz, F; Comi, G; Coyle, PK; Cree, BA; Freedman, MS; Hartung, HP; Leist, TP; Scaramozza, M; Vermersch, P | 1 |
| Bourdette, D; Cameron, MH | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Obert, J; Tazi, A | 1 |
| Karlsson, MO; Krekels, EH; Munafo, A; Novakovic, AM; Ueckert, S | 1 |
| Battaglini, M; Dangond, F; De Leucio, A; De Stefano, N; Giorgio, A; Giovannoni, G; Hicking, C; Sormani, MP | 1 |
| Call, TG; Go, RS; Goyal, G; Hogan, WJ; Litzow, MR; Shah, MV | 1 |
| Aichberger, KJ; Gleixner, KV; Kretschmer, A; Sperr, WR; Valent, P | 1 |
| Eccersley, LR; Hoffbrand, AV; McNamara, CJ; Rustin, MH | 1 |
| Carroll, WM | 1 |
| Chang, P; Comi, G; Cook, S; Giovannoni, G; Greenberg, SJ; Hamlett, A; Musch, B; Rammohan, K; Rieckmann, P; Soelberg Sørensen, P; Vermersch, P | 1 |
| Bojarska-Junak, A; Chocholska, S; Dmoszynska, A; Klimek, P; Kowal, M; Podhorecka, M | 1 |
| Li, H; Zhang, X | 1 |
| Marriott, JJ; O'Connor, PW | 1 |
| Bonzano, L; De Stefano, N; Roccatagliata, L; Sormani, MP | 1 |
| Al-Toma, A; Kuik, DJ; Mulder, CJ; Schreurs, MW; Tack, GJ; Verbeek, WH; Visser, O | 1 |
| Muir, VJ; Plosker, GL | 1 |
| Allez, M; Amiot, A; Bouhnik, Y; Fieschi, C; Galicier, L; Gornet, JM; Joly, F; Lémann, M; Oksenhendler, E; Treton, X | 1 |
| Graham-Rowe, D | 1 |
| Bergeron, A; Detourmignies, L; Frija, J; Jouneau, S; Lorillon, G; Tazi, A; Wallaert, B | 1 |
| Betticher, D; Cerny, T; Fey, MF; Frickhofen, N; Ghielmini, M; Hess, U; Konwalinka, G; Piguet, D; Racine, C; Rufener, B; Schmitz, SF; Tichelli, A; Tobler, A; von Rohr, A; Wernli, M; Zulian, G | 1 |
| Asano, Y; Chou, T; Etoh, T; Kawano, F; Makino, T; Masuda, M; Matsuoka, M; Ohashi, Y; Saburi, Y; Taguchi, H; Tamura, K; Tobinai, K; Uike, N | 1 |
| Elinder, G; Kimby, E; Sverrisdottir, A | 1 |
| Gibson, J; Ho, PJ; Iland, H; Joshua, DE; Ling, S; Watson, G; Young, G | 1 |
| Al-Toma, A; Goerres, MS; Kerckhaert, JA; Meijer, JW; Mulder, CJ; von Blomberg, BM; Wahab, PJ | 1 |
| Cellier, C; Cerf-Bensussan, N | 1 |
| Lange, BJ; Nichols, KE; Orsey, A; Paessler, M | 1 |
| Ceglarek, B; Czyz, J; Federowicz, I; Holowiecki, J; Kalinka-Warzocha, E; Lech-Maranda, E; Robak, T; Wajs, J; Walewski, J; Warzocha, K | 1 |
| Benfenati, D; Benni, M; Lauria, F; Pileri, S; Poggi, S; Raspadori, D; Rondelli, D; Sabattini, E; Tura, S; Ventura, MA | 1 |
| Curd, JG; Lee, TC; Miller, WE; Piro, LD; Saven, A | 1 |
| Hoffman, MA; Janson, D; Rai, KR; Rose, E | 1 |
| Juliusson, G; Liliemark, J; Porwit, A | 1 |
| Beutler, E; Koziol, JA; McMillan, R; Romine, JS; Sipe, JC; Zyroff, J | 1 |
| Cavallin-Ståhl, E; Juliusson, G; Liliemark, J; Martinsson, U; Porwit, A; Strömberg, M; Svedmyr, E | 1 |
| Brandwein, J; O'Connor, P; Selby, R | 1 |
| Chott, A; Fridrik, MA; Hausmaninger, H; Jäger, G; Kienzer, HR; Krieger, O; Lang, A; Linkesch, W; Neubauer, M; Oppitz, P; Schiller, L; Seewann, HL; Weidinger, G; Zabernigg, A | 1 |
| Bocchia, M; Lauria, F; Marotta, G; Raspadori, D; Rondelli, D; Zinzani, PL | 1 |
| Bosly, A; Delannoy, A; Ferrant, A; Michaux, JL; Van Den Neste, E | 1 |
| Adams, HP; Beutler, E; Koziol, JA; Romine, JS; Sipe, JC; Slivka, LS; Sobel, DF; Wagner, S | 1 |
| Bergmann, L; Chow, KU; Hansmann, ML; Hoelzer, D; Hossfeld, DK; Jäger, E; Leimer, L; Meyer, A; Mitrou, PS; Peters, HD; Rummel, MJ | 1 |
| Krook, JE; Levitt, R; Li, CY; Michalak, JC; Schroeder, G; Tefferi, A; Tschetter, LK; Witzig, TE | 1 |
| Berger, T; Hilbe, W; Konwalinka, G; Thaler, J | 1 |
| Bastie, JN; Castaigne, S; Cazals-Hatem, D; D'Agay, MF; Dabout, D; Daniel, MT; Degos, L; Dombret, H; Flandrin, G; Glaisner, S; Noel-Walter, MP; Poisson, D; Rabian, C | 1 |
| Celsing, F; Cristiansen, I; Delannoy, A; Johnson, SA; Juliusson, G; Karlsson, K; Kimby, E; Lärfars, G; Liliemark, J; Luthman, M; Nilsson, G; Porwit, A; Strömberg, M; Sundström, G; Tidefelt, U; Wallvik, J | 1 |
| Myers, LW | 1 |
| Indrák, K; Papajík, T; Pikalová, Z; Raida, L; Zapletalová, J | 1 |
11 review(s) available for cladribine and Disease Exacerbation
| Article | Year |
|---|---|
[New directions of immunocorrection in multiple sclerosis].
Topics: Alemtuzumab; Cladribine; Disease Progression; Humans; Multiple Sclerosis | 2020 |
[Disease-modifying treatment of secondary progressive multiple sclerosis].
Topics: Cladribine; Disease Progression; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2021 |
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Topics: Adjuvants, Immunologic; Cladribine; Cohort Studies; Crotonates; Disease Progression; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon beta-1a; Multiple Sclerosis; Nitriles; Publication Bias; Randomized Controlled Trials as Topic; Recurrence; Time Factors; Toluidines | 2017 |
Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatmen
Topics: Cladribine; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Tablets; Treatment Outcome | 2019 |
Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Adult; Benzamides; Bone Marrow; CD2 Antigens; Cladribine; Disease Progression; Humans; Imatinib Mesylate; Interferon-alpha; Interleukin-2 Receptor alpha Subunit; Mast Cells; Mastocytosis, Systemic; Mutation; Palliative Care; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Factors; Tryptases | 2013 |
[Pulmonary manifestations of Langerhans cell histiocytosis].
Topics: Age of Onset; Antigens, CD1; Cladribine; Combined Modality Therapy; Diagnostic Techniques, Respiratory System; Disease Progression; Diuretics; Endothelin Receptor Antagonists; Histiocytes; Histiocytosis, Langerhans-Cell; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Lung Transplantation; Mutation, Missense; Oncogenes; Oxygen Inhalation Therapy; Phosphodiesterase Inhibitors; Point Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Radiography; Smoking; Smoking Cessation | 2015 |
Emerging therapies in relapsing-remitting multiple sclerosis.
Topics: Adjuvants, Immunologic; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cladribine; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome | 2010 |
Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
Topics: Administration, Oral; Brain; Cladribine; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Predictive Value of Tests; Propylene Glycols; Recurrence; Regression Analysis; Reproducibility of Results; Sphingosine; Time Factors; Treatment Outcome | 2011 |
Cladribine tablets: in relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Animals; Cladribine; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2011 |
Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Adult; Bone Marrow Examination; Cell Lineage; Cladribine; Clinical Trials as Topic; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Immunophenotyping; Interferon-alpha; Leukemia, Mast-Cell; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Organ Specificity; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Assessment; Staurosporine; Tryptases | 2012 |
Immunologic therapy for secondary and primary progressive multiple sclerosis.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antilymphocyte Serum; Autoimmune Diseases; Cladribine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Forecasting; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Multiple Sclerosis; Peptides; Plasma Exchange; Randomized Controlled Trials as Topic; Steroids; T-Lymphocytes; Treatment Outcome; Vaccination | 2001 |
23 trial(s) available for cladribine and Disease Exacerbation
| Article | Year |
|---|---|
Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets.
Topics: Atrophy; Brain; Cladribine; Disease Progression; Gray Matter; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2023 |
Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
Topics: Adult; Algorithms; Cladribine; Disease Progression; Germany; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Placebo Effect; Tablets | 2020 |
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Topics: Adult; Cladribine; Disease Progression; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Severity of Illness Index | 2019 |
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
Topics: Cladribine; Confounding Factors, Epidemiologic; Disability Evaluation; Disease Progression; Drug Substitution; Humans; Immunosuppressive Agents; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Patient Dropouts; Time Factors; Treatment Outcome | 2019 |
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Topics: Administration, Oral; Adolescent; Adult; Cladribine; Demyelinating Diseases; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Time Factors; Treatment Outcome; Young Adult | 2014 |
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
Topics: Adolescent; Adult; Aged; Atrophy; Brain; Cladribine; Disease Progression; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Risk; Young Adult | 2018 |
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analysis of Variance; Brain; Cladribine; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Lymphopenia; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Young Adult | 2010 |
Evaluation of Cladribine treatment in refractory celiac disease type II.
Topics: Adult; Aged; Celiac Disease; Cladribine; Cohort Studies; Disease Progression; Female; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Remission Induction | 2011 |
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease Progression; Female; Humans; Injections, Subcutaneous; Leukemia, Hairy Cell; Leukopenia; Male; Middle Aged; Recurrence; Survival | 2002 |
Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease Progression; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Remission Induction; Salvage Therapy; Treatment Failure | 2003 |
Cladribine therapy in refractory celiac disease with aberrant T cells.
Topics: Aged; Celiac Disease; Cladribine; Disease Progression; Female; Genes, T-Cell Receptor gamma; Humans; Immunophenotyping; Immunosuppressive Agents; Lymphocyte Depletion; Lymphoma, T-Cell; Male; Middle Aged; Prospective Studies; T-Lymphocytes | 2006 |
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Disease Progression; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Staging; Poland; Prednisone; Survival Rate; Vincristine | 2008 |
Retreatment with 2-CdA of progressed HCL patients.
Topics: Adult; Aged; Cladribine; Disease Progression; Female; Humans; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged | 1994 |
Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma.
Topics: Cladribine; Disease Progression; Dose-Response Relationship, Drug; Humans; Infections; Leukopenia; Lymphoma, Non-Hodgkin; Survival Rate; Thrombocytopenia | 1997 |
Development of cladribine treatment in multiple sclerosis.
Topics: Cladribine; Cross-Over Studies; Disease Progression; Double-Blind Method; Humans; Immunosuppressive Agents; Multiple Sclerosis | 1996 |
Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Transformation, Neoplastic; Cladribine; Disease Progression; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Middle Aged; Platelet Count; Survival Analysis; Thrombocytopenia; Treatment Outcome | 1998 |
Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chronic Disease; Cladribine; Disability Evaluation; Disease Progression; Female; Humans; Immunosuppressive Agents; Injections, Subcutaneous; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis; Safety; Treatment Outcome | 1998 |
Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease Progression; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Failure | 1998 |
Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cladribine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infection Control; Interferon-alpha; Leukemia, Hairy Cell; Lymphopenia; Male; Middle Aged; Neutropenia; Pentostatin; Remission Induction; Treatment Outcome | 1999 |
Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.
Topics: Adult; Cladribine; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Neurologic Examination; Placebos; Treatment Outcome | 1999 |
Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Germany; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Recurrence; Remission Induction; Treatment Outcome | 1999 |
Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Survival Analysis; United States | 1999 |
Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm, Residual; Opportunistic Infections; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2002 |
35 other study(ies) available for cladribine and Disease Exacerbation
| Article | Year |
|---|---|
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Topics: Cladribine; Cohort Studies; Disability Evaluation; Disease Progression; Female; Humans; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic | 2022 |
Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Topics: Adult; Age of Onset; Cladribine; Cost-Benefit Analysis; Disease Progression; Female; Fingolimod Hydrochloride; Health Expenditures; Health Resources; Humans; Immunosuppressive Agents; Male; Markov Chains; Middle Aged; Models, Economic; Multiple Sclerosis, Relapsing-Remitting; Portugal; Quality-Adjusted Life Years | 2020 |
Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
Topics: Child; Child, Preschool; Cladribine; Cyclosporine; Disease Progression; Egypt; Female; Histiocytosis, Langerhans-Cell; Humans; Infant; Langerhans Cells; Liver; Lymph Nodes; Lymphohistiocytosis, Hemophagocytic; Male; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2020 |
Cladribine vs other drugs in MS: Merging randomized trial with real-life data.
Topics: Adult; Cladribine; Databases, Factual; Datasets as Topic; Disease Progression; Female; Humans; Immunologic Factors; Male; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis, Relapsing-Remitting; Observational Studies as Topic; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index | 2020 |
Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis.
Topics: Adult; Aged; Cladribine; Combined Modality Therapy; Disease Progression; Drug Evaluation; Female; Histiocytosis, Langerhans-Cell; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; MAP Kinase Signaling System; Middle Aged; Mutation, Missense; Point Mutation; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Pulmonary Diffusing Capacity; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Topics: Adult; Cladribine; Disease Progression; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Retrospective Studies | 2021 |
Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Topics: Adult; Alemtuzumab; Cladribine; Cost-Benefit Analysis; Disability Evaluation; Disease Progression; Female; Health Resources; Humans; Immunosuppressive Agents; Male; Markov Chains; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Quality-Adjusted Life Years; United Kingdom | 2018 |
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Cladribine; Disease Progression; Fatal Outcome; Humans; Janus Kinase 2; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Leukopenia; Male; Neutropenia; Oral Ulcer; Polycythemia Vera; Primary Myelofibrosis; Splenomegaly; Thrombocytopenia | 2018 |
Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.
Topics: Adult; Cladribine; Disease Progression; Female; Humans; Immunosuppressive Agents; Isoelectric Focusing; Male; Multiple Sclerosis, Relapsing-Remitting; Oligoclonal Bands; Prospective Studies; Treatment Outcome | 2019 |
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Topics: Adult; Cladribine; Cost-Benefit Analysis; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Quality-Adjusted Life Years; Spain | 2020 |
Langerhans cell sarcoma of the nasopharynx: a rare case.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cladribine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Humans; Langerhans Cell Sarcoma; Male; Nasopharyngeal Neoplasms; Prednisone | 2013 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult | 2014 |
New treatments for multiple sclerosis: at what long-term risk?
Topics: Cladribine; Disease Progression; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis.
Topics: Cladribine; Clinical Trials, Phase III as Topic; Disability Evaluation; Disease Progression; Humans; Immunosuppressive Agents; Logistic Models; Models, Theoretical; Multiple Sclerosis, Relapsing-Remitting; Severity of Illness Index | 2017 |
Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Disease Progression; Erdheim-Chester Disease; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis.
Topics: Aged; Antineoplastic Agents; Cladribine; Dasatinib; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Leukemia, Mast-Cell; Mastocytosis, Systemic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure; Tryptases | 2008 |
Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
Topics: Cladribine; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2009 |
Paraneoplastic pemphigus associated with systemic mastocytosis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Disease Progression; Fatal Outcome; Humans; Immunoglobulins, Intravenous; Liver; Male; Mastocytosis, Systemic; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Pentostatin; Prednisone; Pyrimidines; Rituximab; Treatment Failure; Urticaria Pigmentosa | 2009 |
Oral therapy for multiple sclerosis--sea change or incremental step?
Topics: Administration, Oral; Arrhythmias, Cardiac; Cladribine; Disease Progression; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2010 |
Assessment of peripheral blood and bone marrow cells apoptosis caused by purine analogues in patients with chronic lymphocytic leukemia in correlation with parameters of disease progression.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Apoptosis; B-Lymphocyte Subsets; bcl-2-Associated X Protein; Biomarkers; Bone Marrow Cells; Caspase 3; Chronic Disease; Cladribine; Disease Progression; Enzyme Activation; Humans; Leukemia, Lymphoid; Membrane Glycoproteins; Prognosis; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2010 |
Oral cladribine and fingolimod for relapsing multiple sclerosis.
Topics: Administration, Oral; Cladribine; Disability Evaluation; Disease Progression; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting | 2010 |
High frequency of fatal haemophagocytic lymphohistiocytosis syndrome in enteropathy-associated T cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease Progression; Disease-Free Survival; Enteropathy-Associated T-Cell Lymphoma; Female; Humans; Kaplan-Meier Estimate; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Neutropenia; Purine Nucleotides; Retrospective Studies | 2012 |
Drugs: An injection of hope.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2012 |
Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis.
Topics: Adult; Cladribine; Disease Progression; Dyspnea; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Male; Tomography, X-Ray Computed; Young Adult | 2012 |
Safety of rituximab therapy during the first trimester of pregnancy: a case history.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cladribine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant, Newborn; Lymphoma, Follicular; Male; Methotrexate; Mitoguazone; Peripheral Blood Stem Cell Transplantation; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Remission Induction; Rituximab; Safety; Transplantation, Autologous; Vincristine | 2004 |
Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?
Topics: Aged; Antineoplastic Agents, Alkylating; Cell Transformation, Neoplastic; Cladribine; Disease Progression; Fatal Outcome; Female; Humans; Immunosuppression Therapy; Lymphoma, Large B-Cell, Diffuse; Male; Purine Nucleosides; Waldenstrom Macroglobulinemia | 2006 |
Treatment of clonal refractory celiac disease or cryptic intraepithelial lymphoma: A long road from bench to bedside.
Topics: Celiac Disease; Cladribine; Disease Progression; Humans; Immunosuppressive Agents; Interleukin-15; Lymphoma, T-Cell | 2006 |
Central nervous system juvenile xanthogranuloma with malignant transformation.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Brain Neoplasms; Child; Cladribine; Dexamethasone; Diagnosis, Differential; Disease Progression; Fatal Outcome; Histiocytic Sarcoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Magnetic Resonance Imaging; Male; Pseudotumor Cerebri; Radiotherapy; Xanthogranuloma, Juvenile | 2008 |
Prolonged, complete remission after 2-chlorodeoxyadenosine therapy in a patient with refractory essential mixed cryoglobulinemia.
Topics: Aged; Cladribine; Cryoglobulinemia; Disease Progression; Humans; Immunosuppressive Agents; Male; Remission Induction | 1996 |
Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neutropenia; Phenotype; Recurrence; Remission Induction | 1997 |
Cladribine for Waldenström's macroglobulinaemia.
Topics: Cladribine; Disease Progression; Humans; Immunosuppressive Agents; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia | 1999 |
Cladribine treatment of a patient with hairy cell leukemia and concomitant multiple sclerosis.
Topics: Antineoplastic Agents; Cladribine; Disease Progression; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Multiple Sclerosis | 1999 |
Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Marrow; CD4 Lymphocyte Count; Cladribine; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infections; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Second Primary; Opportunistic Infections; Pentostatin; Remission Induction; Splenectomy; Survival Rate | 1999 |
[Therapeutic effectiveness of cladribine and cellular immunodeficiency--related effects in hairy-cell leukemia?].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CD4 Lymphocyte Count; CD56 Antigen; CD8-Positive T-Lymphocytes; Cladribine; Disease Progression; Female; Humans; Immunosuppressive Agents; Leukemia, Hairy Cell; Lymphocytes; Male; Middle Aged; Recurrence; Remission Induction | 2002 |